Market open
Cassava Sciences/$SAVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cassava Sciences
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Ticker
$SAVA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
30
ISIN
US14817C1071
Website
Cassava Sciences Metrics
BasicAdvanced
$91M
-
-$1.53
-2.32
-
Price and volume
Market cap
$91M
Beta
-2.32
52-week high
$42.20
52-week low
$1.15
Average daily volume
944K
Financial strength
Current ratio
9.077
Quick ratio
8.864
Management effectiveness
Return on assets (TTM)
-62.83%
Return on equity (TTM)
-70.59%
Valuation
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-0.82
Growth
Earnings per share change (TTM)
-29.71%
3-year earnings per share growth (CAGR)
9.59%
What the Analysts think about Cassava Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cassava Sciences stock.
Cassava Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cassava Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cassava Sciences News
AllArticlesVideos
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
GlobeNewsWire·2 weeks ago
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
GlobeNewsWire·3 weeks ago
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cassava Sciences stock?
Cassava Sciences (SAVA) has a market cap of $91M as of May 15, 2025.
What is the P/E ratio for Cassava Sciences stock?
The price to earnings (P/E) ratio for Cassava Sciences (SAVA) stock is 0 as of May 15, 2025.
Does Cassava Sciences stock pay dividends?
No, Cassava Sciences (SAVA) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Cassava Sciences dividend payment date?
Cassava Sciences (SAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cassava Sciences?
Cassava Sciences (SAVA) has a beta rating of -2.32. This means that it has an inverse relation to market volatility.